Display options
Cite
Beroza P, Villar HO, Wick MM, et al. Chemoproteomics as a basis for post-genomic drug discovery. Drug Discov Today. 2002;7(15):807-14doi: 10.1016/s1359-6446(02)02371-1.
Beroza, P., Villar, H. O., Wick, M. M., & Martin, G. R. (2002). Chemoproteomics as a basis for post-genomic drug discovery. Drug discovery today, 7(15), 807-14. https://doi.org/10.1016/s1359-6446(02)02371-1
Beroza, Paul, et al. "Chemoproteomics as a basis for post-genomic drug discovery." Drug discovery today vol. 7,15 (2002): 807-14. doi: https://doi.org/10.1016/s1359-6446(02)02371-1
Beroza P, Villar HO, Wick MM, Martin GR. Chemoproteomics as a basis for post-genomic drug discovery. Drug Discov Today. 2002 Aug 01;7(15):807-14. doi: 10.1016/s1359-6446(02)02371-1. PMID: 12546968.
Copy Download .nbib Format: NLM
Share it on

Drug Discov Today. 2002 Aug 01;7(15):807-14. doi: 10.1016/s1359-6446(02)02371-1.

Chemoproteomics as a basis for post-genomic drug discovery.

Drug discovery today

Paul Beroza, Hugo O Villar, Michael M Wick, Graeme R Martin

Affiliations

  1. Telik, 750 Gateway Blvd, South San Francisco, CA 94080, USA. [email protected]

PMID: 12546968 DOI: 10.1016/s1359-6446(02)02371-1

Abstract

The large number of small organic compounds now available for drug-lead screening has led to numerous methods for classifying molecular similarity and diversity, the aim being to restore a balance between the quantity and drug-like quality of compounds in small-molecule libraries. Whereas structural and physicochemical attributes continue to be emphasized in compound selection for drug-lead screening, chemoproteomics--the use of biological information to guide chemistry--offers a highly efficient alternative to small-molecule characterization that can accelerate drug discovery in the post-genomic era.

Substances

MeSH terms

Publication Types